Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24 Month, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Trial Profile

A 24 Month, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms RAD
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2018 Results of a pooled analysis from H2304 and H2307 studies, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top